Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SOX plus envafolimab neoadjuvant phase II study in advanced gastric cancer
ChiCTR2200057814Phase 2Not yet recruiting
- Sponsor
- Jiangsu Provincial People's Hospital
- Start
- Mar 2022
- Modality
- Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Nanobodies (VHH) → Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of envafolimab, oxaliplatin and tegafur in gastric cancer (GC) and gastroesophageal junction adenocarcinoma, sponsored by Jiangsu Provincial People's Hospital. Primary endpoint: Major pathological response rate. Planned start Mar 2022; status: not yet recruiting.
02
Drugs
envafolimaboxaliplatintegafur
03
Conditions
gastric cancer (GC)gastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on ChiCTR2200057814.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200057814.